RNAC earnings analysis
What we found in RNAC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
RNAC reported a significant decline in total revenue, falling to $78,000 for Q1 2026 from $1.1 million in Q1 2025, a decrease of 93%. The company also faced a net loss of $39.2 million, which more than doubled compared to the prior year's net loss of $17.7 million due to increasing operating expenses and a significant change in fair value of liabilities. Management highlighted ongoing challenges in product development and indicated the need for additional financing to sustain operations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Severe Revenue Drop
- Total revenue fell to $78,000, down 93% from $1.1 million in Q1 2025.
- Excessive Net Loss
- The net loss for Q1 2026 was $39.2 million, increasing by 121% from $17.7 million in Q1 2025.
- R&D Expenses Surge
- Research and development expenses rose 33% to $19.5 million, up from $14.7 million year-over-year.
- Lower Interest Income
- Interest income decreased to $1.0 million, down 49% from $2.0 million a year ago.
- Management Comments on Cash Needs
- Management stated they will require substantial additional funding to continue operations and pursue product development.
- Decrease in Grant Revenue
- Grant revenue dropped to $78,000 from $700,000 in Q1 2025, reflecting reduced eligible expenses.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Higher Operating Losses
- Operating loss increased to $26.5 million, up 21% from $21.9 million in Q1 2025.
- Escalating Debt Level
- Accumulated deficit reached $861.6 million, indicating a long-standing financial struggle.
- Funding Challenges Ahead
- Management warned of potential difficulties in raising necessary capital to support ongoing development.
What they said about what is next.
Management anticipates continued losses and the need for additional financing, but did not provide specific numeric guidance in the report.
The filing reads worse than the one before it.
What came before.
- 10-K · March 9, 2026
- Cartesian Therapeutics (RNAC) shows strong clinical progress for lead candidate Descartes-08 — >100 patients treated as of December 31, 2025, Phase 3 AURORA initiated in May 2025 with ~100 participants and an SPA from…
- 10-Q · November 6, 2025
- Cartesian Therapeutics reported Q3 2025 revenue of $452,000 (grant revenue), up from $387,000 in Q3 2024 and $298,000 in Q2 2025, while reporting a net loss of $35.9 million (loss per share $1.38) driven by $21.5…
- 10-K · March 13, 2025
- Cartesian Therapeutics (RNAC) frames itself as a clinical-stage mRNA cell therapy company focused on autoimmune diseases, leading with Descartes-08 (anti-BCMA) which achieved statistically significant Phase 2b results.…
- 10-Q · May 8, 2024
- Cartesian Therapeutics reported collaboration and license revenue of $5,840,000 and a GAAP net loss of $56,824,000 (EPS -$10.50) for the quarter ended March 31, 2024. Cash and equivalents totaled ~$104.8M and management…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RNAC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever